$RNA
Avidity Biosciences, Inc. Stock $rna

$rna Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000159990123000030 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$2.316M	$2.233M	$2.769M
YoY Change	6.34%	24.4%	49.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.28M	$12.06M	$10.38M
YoY Change	41.32%	40.82%	39.74%
% of Gross Profit
Research & Development	$42.67M	$47.77M	$45.61M
YoY Change	7.25%	72.51%	38.35%
% of Gross Profit
Depreciation & Amortization	$529.0K	$400.0K	$381.0K
YoY Change	64.29%	33.33%	83.17%
% of Gross Profit
Operating Expenses	$54.95M	$59.83M	$55.99M
YoY Change	13.35%	65.02%	38.6%
Operating Profit	-$52.63M	-$57.60M
YoY Change	13.68%	67.14%
Interest Expense	$5.771M	$5.516M	$2.772M
YoY Change	844.52%	2106.4%	4940.0%
% of Operating Profit
Other Income/Expense, Net	-$162.0K	$5.202M	-$18.00K
YoY Change	8000.0%	-20908.0%	-60.87%
Pretax Income	-$47.03M	-$52.39M	-$50.47M
YoY Change	2.92%	53.04%	30.96%
Income Tax
% Of Pretax Income
Net Earnings	-$47.03M	-$52.39M	-$50.47M
YoY Change	2.92%	53.04%	30.96%
Net Earnings / Revenue	-2030.44%	-2346.35%	-1822.72%
Basic Earnings Per Share	-$0.66	-$0.74
Diluted Earnings Per Share	-$0.66	-$0.74	-$0.88
COMMON SHARES
Basic Shares Outstanding	70.82M shares	70.81M shares	54.46M
Diluted Shares Outstanding	71.39M shares	70.43M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$576.5M	$586.3M	$610.7M
YoY Change	44.77%	47.66%	50.59%
Cash & Equivalents	$153.9M	$118.7M	$340.4M
Short-Term Investments	$422.6M	$467.6M	$270.3M
Other Short-Term Assets	$18.03M	$10.85M	$12.22M
YoY Change	198.87%	40.34%	118.2%
Inventory
Prepaid Expenses	$10.99M		$8.340M
Receivables	$1.183M		$2.364M
Other Receivables	$0.00
Total Short-Term Assets	$594.5M	$597.1M	$622.9M
YoY Change	47.07%	47.52%	51.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.53M	$7.845M	$6.254M
YoY Change	-2.22%	56.0%	30.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$719.0K	$474.0K	$598.0K
YoY Change	7.96%	-54.81%	-0.17%
Total Long-Term Assets	$16.25M	$16.83M	$15.86M
YoY Change	-1.81%	3.02%	-3.53%
TOTAL ASSETS
Total Short-Term Assets	$594.5M	$597.1M	$622.9M
Total Long-Term Assets	$16.25M	$16.83M	$15.86M
Total Assets	$610.8M	$614.0M	$638.8M
YoY Change	45.15%	45.79%	49.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$31.76M	$3.908M	$4.637M
YoY Change	54.52%	-79.24%	-67.08%
Accrued Expenses	$9.678M	$9.138M	$14.30M
YoY Change	24.8%	34.68%	33.49%
Deferred Revenue	$3.810M	$5.057M	$5.041M
YoY Change			3.64%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$45.24M	$48.09M	$51.91M
YoY Change	34.31%	55.51%	75.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.362M	$6.976M	$8.817M
YoY Change	-50.15%	-51.91%	-46.54%
Total Long-Term Liabilities	$6.362M	$6.976M	$8.817M
YoY Change	-50.15%	-51.91%	-46.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.24M	$48.09M	$51.91M
Total Long-Term Liabilities	$6.362M	$6.976M	$8.817M
Total Liabilities	$51.61M	$55.06M	$60.73M
YoY Change	11.1%	21.21%	31.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$458.0M	-$410.9M	-$358.5M
YoY Change		87.8%	94.31%
Common Stock	$1.020B	$971.4M	$7.000K
YoY Change		62.84%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$559.2M	$558.9M	$578.1M
YoY Change
Total Liabilities & Shareholders Equity	$610.8M	$614.0M	$638.8M
YoY Change	45.15%	45.79%	49.4%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$47.03M	-$52.39M	-$50.47M
YoY Change	2.92%	53.04%	30.96%
Depreciation, Depletion And Amortization	$529.0K	$400.0K	$381.0K
YoY Change	64.29%	33.33%	83.17%
Cash From Operating Activities	-$49.81M	-$48.97M	-$39.19M
YoY Change	40.12%	65.57%	49.49%
INVESTING ACTIVITIES
Capital Expenditures	$622.0K	$1.820M	$850.0K
YoY Change	-147.05%	140.11%	-149.79%
Acquisitions
YoY Change
Other Investing Activities	$46.67M	-$193.9M	-$6.918M
YoY Change	-385.94%	10.96%	-91.6%
Cash From Investing Activities	$46.05M	-$195.7M	-$7.768M
YoY Change	-360.99%	11.51%	-90.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	38.97M	$22.96M	243.7M
YoY Change	0.48%	-4.78%	1076.28%
NET CHANGE
Cash From Operating Activities	-49.81M	-$48.97M	-39.19M
Cash From Investing Activities	46.05M	-$195.7M	-7.768M
Cash From Financing Activities	38.97M	$22.96M	243.7M
Net Change In Cash	35.21M	-$221.7M	196.7M
YoY Change	-344.44%	26.33%	-319.61%
FREE CASH FLOW
Cash From Operating Activities	-$49.81M	-$48.97M	-$39.19M
Capital Expenditures	$622.0K	$1.820M	$850.0K
Free Cash Flow	-$50.43M	-$50.79M	-$40.04M
YoY Change	47.35%	67.44%	63.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001599901
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39321
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Avidity Biosciences, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1336960
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10578 Science Center Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	401-7900
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	RNA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70819170	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118710000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	340396000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	467590000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	270331000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10847000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	12215000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	597147000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	622942000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7845000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6254000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	251000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	251000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8259000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8755000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	474000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	598000	usd
CY2023Q1	us-gaap	Assets Assets	613976000	usd
CY2022Q4	us-gaap	Assets Assets	638800000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33890000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32572000	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	6009000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	11190000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3129000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3105000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5057000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5041000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	48085000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51908000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6976000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7582000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1235000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	55061000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	60725000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70813000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70813000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69768000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69768000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	375708000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	971375000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	939310000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1529000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2698000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410938000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358544000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	558915000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	578075000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	613976000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	638800000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2233000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1795000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47765000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27688000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12064000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8567000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	59829000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	36255000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-57596000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-34460000	usd
CY2023Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5516000	usd
CY2022Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	250000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-314000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5202000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	225000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-52394000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-34235000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1169000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1839000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51225000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36074000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70433000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70433000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48246000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48246000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	381430000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	745000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24103000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6238000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-34235000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1839000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	578075000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	520000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	408000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22441000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9104000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-52394000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1169000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	558915000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-52394000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-34235000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	391000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	314000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9104000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6238000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2231000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-164000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	688000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	689000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1491000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2080000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1158000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4957000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5181000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4699000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-774000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1219000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-922000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48967000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29574000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	57490000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	251350000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	174717000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1820000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	758000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195680000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-175475000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	22441000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24103000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	520000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22961000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24113000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-221686000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-180936000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340647000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	320699000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118961000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139763000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	162000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410900000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	586300000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed financial statements are prepared in accordance with GAAP, which requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the condensed financial statements and accompanying notes. The most significant estimates in the Company’s condensed financial statements relate to revenue recognition, stock-based compensation, and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33890000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	usd
CY2023Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity. The Company has not experienced any losses in its accounts and </span></div>believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held.
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3908000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4637000	usd
CY2023Q1	rna	Accrued Non Clinical Liabilities Current AccruedNonClinicalLiabilitiesCurrent	26325000	usd
CY2022Q4	rna	Accrued Non Clinical Liabilities Current AccruedNonClinicalLiabilitiesCurrent	22535000	usd
CY2023Q1	rna	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	3657000	usd
CY2022Q4	rna	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	5400000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32572000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11624000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8307000	shares
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	469119000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	110000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1639000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	467590000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	273029000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2701000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	270331000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	1600000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	900000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1300000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6276000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1219000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5057000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11356000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9374000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3511000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3120000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7845000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6254000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	400000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	300000	usd
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9352000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.28
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1759000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.40
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	102000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	36000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.73
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10973000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9104000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6238000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	84600000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001599901-23-000030-index-headers.html	Edgar Link	pending
0001599901-23-000030-index.html	Edgar Link	pending
0001599901-23-000030.txt	Edgar Link	pending
0001599901-23-000030-xbrl.zip	Edgar Link	pending
avidity-nonxemployeedirect.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rna-20230331.htm	Edgar Link	pending
rna-20230331.xsd	Edgar Link	pending
rna-20230331xex312.htm	Edgar Link	pending
rna-20230331xex321.htm	Edgar Link	pending
rna-20230331xex322.htm	Edgar Link	pending
rna-20230331xexx311.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rna-20230331_cal.xml	Edgar Link	unprocessable
rna-20230331_def.xml	Edgar Link	unprocessable
rna-20230331_lab.xml	Edgar Link	unprocessable
rna-20230331_pre.xml	Edgar Link	unprocessable
rna-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNA
Avidity Biosciences, Inc. Stock $rna

2023 Q2 Form 10-Q Financial Statement

#000159990123000030 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNA Avidity Biosciences, Inc. Stock $rna

2023 Q2 Form 10-Q Financial Statement

#000159990123000030 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNA
Avidity Biosciences, Inc. Stock $rna